公司 Logicore 数字微流控业务目前处于终端产品持续开发进程中，并初步拓展海外市场，尚处于商业 化初期，未正式产生规模化的商业收入。通过本次增资扩股，公司将进一步整合现有数字微流控业务， 在保证对其持续投入资金的同时，提高各项资源利用率，合理分摊投资风险，有利于促进公司数字微流 控业务规划的战略落地，帮助提升公司整体竞争力水平。 格隆汇11月19日丨诺唯赞(688105.SH)公布，为进一步整合公司数字微流控业务、拓展诊断领域国际业 务，公司下属控股子公司Logilet（UK）根据自身经营发展需要与长期业务规划，拟通过增资扩股的方 式引入战略投资者，国君创投SPV、南创投、九安香港、华西银峰拟分别以人民币3,000万元的等值美 元、人民币2,000万元或等值美元、美元400万元、人民币2,000万元或等值美元认购Logilet（UK）新增 A轮优先股。公司全资子公司海南诺唯赞及液滴英国其他股东纽瑞格、荣耀资本均放弃本次增资的优先 认购权。 公司本次放弃液滴英国的优先认购权，系基于公司整体战略规划，结合公司数字微流控业务开展需要和 资本运作规划的综合考虑。本次增资完成后，液滴英国仍为公司控股子公司，不会导 ...

每经头条（nbdtoutiao）——爱泼斯坦案文件解密倒计时，美国会"秒过"法案直通特朗普，引爆两党"极 限撕扯" （记者 曾健辉） 2024年1至12月份，诺唯赞的营业收入构成为：研究和试验发展占比85.17%，医药制造业占比14.66%， 其他业务占比0.17%。 截至发稿，诺唯赞市值为93亿元。 每经AI快讯，诺唯赞（SH 688105，收盘价：23.3元）11月19日晚间发布公告称，公司第二届第二十次 董事会会议于2025年11月19日以通讯表决的方式召开。会议审议了《关于提请召开2025年第二次临时股 东会的议案》等文件。 ...

证券代码：688105 证券简称：诺唯赞 公告编号：2025-050 南京诺唯赞生物科技股份有限公司 关于控股子公司增资扩股暨引入外部投资者 且公司为控股子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 南京诺唯赞生物科技股份有限公司（以下简称"公司"或"诺唯赞"） 下属控股子公司 LOGILET(UK) LIMITED（以下简称"Logilet（UK）"或"液滴 英国"）拟增资扩股并引入外部投资者。国泰君安创新投资有限公司（以下简称 "国君创投"）指定的投资主体（以实际注册信息为准，以下简称"国君创投 SPV"）、南京市紫金生物医药产业投资基金合伙企业（有限合伙）（以下简称 "南创投"）、九安香港有限公司（ANDON HONG KONG CO., LIMITED，以下简称 "九安香港"）与华西银峰投资有限责任公司（以下简称"华西银峰"），拟分 别以人民币 3,000 万元的等值美元、人民币 2,000 万元或等值美元、美元 400 万元、人民币 2,000 万元或等值美元认购 Logi ...

证券代码：688105 证券简称：诺唯赞 公告编号：2025-051 南京诺唯赞生物科技股份有限公司 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 12 月 5 日 15 点 00 分 召开地点：南京市栖霞区科创路红枫科技园 D2 栋公司 1 楼报告厅 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 12 月 5 日至2025 年 12 月 5 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 1 股东会召开日期：2025年12月5日 本次 ...

证券代码：688105 证券简称：诺唯赞 公告编号：2025-049 南京诺唯赞生物科技股份有限公司 第二届董事会第二十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京诺唯赞生物科技股份有限公司(以下简称"公司")第二届董事会第二十 次会议（以下简称"会议"）于 2025 年 11 月 13 日以邮件方式向全体董事发出 会议通知，并于 2025 年 11 月 19 日以通讯表决的方式召开。本次会议的通知、 召开及审议程序符合《公司法》等有关法律法规及《公司章程》的规定。会议审 议通过如下议案： 1、审议通过《关于控股子公司增资扩股暨引入外部投资者且公司为控股子 公司提供担保的议案》 证券代码：688105 证券简称：诺唯赞 公告编号：2025-049 经审议，董事会认为通过本次增资扩股，可进一步整合公司现有数字微流控 业务，提高各项资源利用率，合理分摊投资风险，有利于促进公司数字微流控业 务规划的战略落地，帮助提升公司整体竞争力水平。公司本次放弃对控股子公司 的优先认购权，系基于公司整体战略规划并结合实 ...

Core Insights - The biopharmaceutical sector experienced a decline of 0.98% on November 18, with He Yuan Bio leading the drop [1] - The Shanghai Composite Index closed at 3939.81, down 0.81%, while the Shenzhen Component Index closed at 13080.49, down 0.92% [1] Stock Performance Summary - Notable gainers included: - Aopu Mai (688293) with a closing price of 58.80, up 3.38% on a trading volume of 15,900 shares and a transaction value of 93.39 million [1] - Jin Hu Ke (688670) at 26.80, up 2.88% with a volume of 116,300 shares and a transaction value of 319 million [1] - Te Bao Bio (688278) at 77.08, up 1.22% with a volume of 10,800 shares and a transaction value of 82.57 million [1] - Notable decliners included: - Bu Yuan Bio (688765) at 79.95, down 3.89% with a volume of 56,800 shares and a transaction value of 458 million [2] - San Sheng Guo Jian (688336) at 67.60, down 3.87% with a volume of 68,100 shares and a transaction value of 469 million [2] - Wo Wu Bio (300357) at 31.77, down 3.23% with a volume of 77,900 shares and a transaction value of 250 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 981 million from institutional investors, while retail investors contributed a net inflow of 819 million [2] - Key stocks with significant capital flow included: - Hua Lan Vaccine (301207) with a net inflow of 48.51 million from institutional investors [3] - Rong Chang Bio (688331) with a net inflow of 23.62 million from institutional investors [3] - Jin Ke (688670) with a net inflow of 5.53 million from institutional investors [3]

Investment Rating - The report rates the Chinese life sciences upstream industry as "outperforming the market" [38]. Core Insights - The Chinese life sciences upstream industry is experiencing an upward trend, benefiting from increased R&D spending in the pharmaceutical sector, a recovery in financing for innovative drugs, and a surge in domestic innovative drug exports [1][4]. - There is significant potential for domestic substitution, which is expected to drive long-term growth in the domestic upstream industry [1][4]. - Domestic companies are narrowing the technological gap with international giants through continuous investment in technology, gaining customer recognition and market share [1]. Summary by Sections Industry Overview - The report highlights that the pharmaceutical industry is the most important client for the life sciences upstream sector in China, with R&D demand maintaining growth despite fluctuations [4]. - Key indicators of recovery include sustained growth in R&D spending by large pharmaceutical companies and biotech firms post-COVID-19, a significant increase in domestic innovative drug export transactions, and a resurgence in financing for innovative drugs [4][18]. Domestic Companies - Domestic companies are leveraging technological barriers, cost advantages, and policy opportunities to increase market share [4]. - The average R&D expense ratio for leading domestic upstream companies was 13.0% in the first half of 2025, exceeding levels during the pandemic [4]. - Notable domestic companies include Nanwei Technology, Nuoviz, and Aopumai, which have shown strong revenue growth and technological advancements [1][4][29]. Market Trends - The report indicates that the domestic market for life sciences is characterized by a fragmented structure, with significant growth opportunities arising from the need for domestic substitution due to geopolitical risks and supply chain disruptions [4]. - The report provides data on the increasing domestic market share of various products, such as culture media and chromatography materials, with notable growth in their localization rates [28][30].

Macro Economic Overview - China's economy is experiencing a comprehensive slowdown in October, but is expected to achieve an annual growth target of 5%. Real estate prices are declining rapidly, and retail sales growth has dropped to a one-year low due to the phasing out of old-for-new subsidy policies [5][6] - Fixed asset investment has seen a significant decline, the second largest since February 2020, with fiscal expansion slowing down and anti-involution measures suppressing infrastructure and manufacturing investments. However, due to a strong economic growth rate in the first half of the year, a GDP growth rate of only 4.5% is needed in the fourth quarter to meet the annual target [5][6] Industry Insights - The Chinese life sciences upstream industry is benefiting from several positive trends, including increased R&D spending by downstream pharmaceutical companies, a recovery in financing for innovative drugs, and a continued surge in the export of Chinese innovative drugs. Domestic companies are narrowing the technological gap with international giants through sustained investment [6][7] - The domestic upstream industry is expected to see considerable growth driven by domestic substitution, with companies like Nanwei Technology, Novozymes, and Aopumai being highlighted as key players [6][7] - The domestic pharmaceutical industry has maintained growth momentum in R&D demand, with significant increases in financing for innovative drugs, which surged by 443.6% year-on-year in Q3 2025 [6][7] Company Analysis - Baidu is focusing on accelerating AI application deployment, having launched the Wenxin large model 5.0 and new Kunlun chips. The company aims to enhance its core products and expand its global services, with a target price set at $148.40, maintaining a "Buy" rating [8]

Group 1 - The core viewpoint of the news is that NuoVas has experienced fluctuations in its financing activities, with a net financing outflow on November 12, indicating potential investor caution [1] - On November 12, NuoVas had a financing buy-in amount of 3.25 million yuan and a financing repayment of 4.92 million yuan, resulting in a net financing buy-in of -1.67 million yuan [1] - As of November 12, the total financing and securities lending balance for NuoVas was 92.81 million yuan, with a financing balance of 91.97 million yuan, accounting for 0.97% of the circulating market value [1] Group 2 - NuoVas, established on March 16, 2012, is a biotechnology company focused on the research and development of functional proteins and high molecular organic materials, with a revenue composition of 81.86% from biological reagents [2] - For the period from January to September 2025, NuoVas reported an operating income of 952 million yuan, a year-on-year decrease of 3.40%, and a net profit attributable to shareholders of 6.62 million yuan, down 63.57% year-on-year [2] - As of September 30, NuoVas had 9,447 shareholders, an increase of 9.90% from the previous period, while the average circulating shares per person decreased by 9.01% to 42,101 shares [2] Group 3 - Since its A-share listing, NuoVas has distributed a total of 731 million yuan in dividends, with 611 million yuan distributed over the past three years [3]

Summary of Key Points Core Viewpoint - NuoVaxan's stock performance and financing activities indicate a mixed sentiment among investors, with a notable decrease in revenue and net profit year-on-year, suggesting potential challenges ahead for the company [1][2]. Group 1: Stock Performance and Financing - On November 11, NuoVaxan's stock rose by 0.17% with a trading volume of 36.08 million yuan [1]. - The financing buy-in amount for NuoVaxan on the same day was 3.48 million yuan, while the financing repayment was 4.09 million yuan, resulting in a net financing outflow of 610,400 yuan [1]. - As of November 11, the total financing and securities lending balance for NuoVaxan was 94.44 million yuan, with the financing balance at 93.64 million yuan, accounting for 0.99% of the circulating market value, indicating a high level compared to the past year [1]. Group 2: Company Overview and Financial Performance - NuoVaxan, established on March 16, 2012, and listed on November 15, 2021, specializes in the research and development of functional proteins and high molecular organic materials, with a focus on biological reagents and in vitro diagnostics [2]. - The company's revenue composition includes 81.86% from biological reagents, 9.99% from diagnostic reagents, 3.15% from consumables, 2.96% from equipment, 1.85% from technical services, and 0.18% from other sources [2]. - For the period from January to September 2025, NuoVaxan reported a revenue of 952 million yuan, a year-on-year decrease of 3.40%, and a net profit attributable to shareholders of 6.62 million yuan, down 63.57% year-on-year [2]. Group 3: Dividend Information - Since its A-share listing, NuoVaxan has distributed a total of 731 million yuan in dividends, with 611 million yuan distributed over the past three years [3].